Experimental drug helping Colfax man with rare auto-immune disorder
By LeAnn R. Ralph
COLFAX — With the help of an experimental drug, Jeremiah Harder is doing much better these days.
Harder, a 2013 graduate of Colfax High School, was diagnosed with Lambert-Eaton Myasthenic Syndrome (LEMS) in the fall of 2015.
LEMS is an auto-immune neuro-musculature disorder that causes weakness of the extremities and difficulty moving the legs and arms as well as difficulty swallowing, chewing and talking.
“I’m one in a million. Most people that get it are 50 years or older and have lung cancer. I don’t have cancer,” Harder said.
Harder first started noticing symptoms in December of 2014.
Getting the correct diagnosis took nine months.
“I go to Rochester to a doctor who has put me on a trial run (of a drug),” Harder said, noting that the physician had much to do with developing the drug.
“She knows a lot about my condition,” he said.
“I’m fortunate to have her. The (drug) that I’m on, for the trial run … is pretty new. Fortunately, it’s on a trial run, because if it wasn’t, it would be pretty expensive,” Harder said.
Estimates are that once the drug is approved by the federal Food and Drug Administration, it could cost as much as $5,000 per month.
“The first time (he took the trial run medication), I couldn’t get out of my recliner. I took the first dose, and 20 minutes later, I could walk. I call it my miracle drug,” Harder said.
The medication is still working quickly and lasts for eight or ten hours, although more frequent doses help keep the level of the drug at a point where it is the most effective.
When the medication is wearing off, often the first thing Harder notices is his speech starts to slur.
“If I take it every four or five hours, that keeps the dose steady,” he said.
“It was frustrating not to get a diagnosis for nine months. I didn’t know what I had. I didn’t know if I was dying,” Harder said.
The drug helps by assisting the nerves to give off a blocked chemical. The blocked chemical is what helps the muscles to contract.
“The summer months are hard for me. I have been really slowing down in the last week. Winter is easier for me,” Harder said.
The heat is what slows him down and makes moving more difficult.
“I can probably only be outside for a couple of hours. I just watch for the cool weather and go outside when it’s cool,” he said.
Early mornings and later in the evening during the summer are generally times that Harder can venture outside.
Harder says he does not really know if intolerance to heat is common with the condition.
LEMS is so rare doctors also do not know if intolerance to heat is a common feature of the condition.
“No one even knows how I got it. They really don’t know that much about it,” he said.
Jeremiah said while no one knows how he ended up with LEMS, he does know he had Lyme disease and thinks it is possible the Lyme bacteria might have worn down his immune system and triggered the auto-immune disease.
“I’m doing a lot better since I got diagnosed, and hopefully, it just keeps improving from now on,” he said.
LEMS patients typically reach a point where they plateau and then do not improve much beyond that point, he said.
Three medications are helping Harder: an IV once a month; another medication he takes twice a day, but which takes six months to a year of dosing before it starts to work; and the medication he takes every four hours.
Harder was active in sports and in 4-H while he was in school.
After high school, Harder attended Vermillion College and graduated in 2014. He had started a taxidermy business and worked at Woods Run Forest Products in Colfax with his brother Joshua and also worked as a carpenter with his brother Jacob.
The community held a benefit for Harder last year. Jeremiah says he appreciates the support of the community, both for the thoughts and prayers he knows are coming his way and for the turnout at the benefit.
“I wouldn’t make it without the support of the community,” he said.
Jeremiah Harder was 21years old when he was diagnosed.
“I’ve come a long ways from where I was,” he said.

